Introduction
The goal of anti-cancer therapy is to induce death of malignant cells. Oncolytic agents induce cytotoxicity directly, or indirectly via antibody dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). To determine the cytotoxicity of a compound in vitro, a number of methods can be applied. The classic method is the chromium 51 ( 51 Cr) release assay, 1, 2 in which target cells are labeled with the radioactive compound 51 Cr. After incubation with the compound of interest plus or minus effector cells or complement the amount of lysed target cells is determined by the amount of radioactivity in the supernatant. Because the use of radioactive compounds requires skilled personnel, costly equipment and laboratories, nonradioactive cytotoxicity assays have been developed that rely on the release of naturally occurring intracellular enzymes like lactate dehydrogenase (LDH) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from dying cells. The readout in these assays is based on a chemical reaction related to the activity of these enzymes. Both the LDH and the GAPDH assay do not discriminate between cell death by the compound under study or non-specific cell death, including that of effector cells, and results have to be compensated for that. 3, 4 Another alternative to the 51 Cr release assay is the calcein release assay. 5, 6 In this assay, target cells are incubated with calcein AM, a non-fluorescent, hydrophobic and cell permeable dye that easily enters living cells.
In the cell cytoplasm, AM is cleaved off by esterases via hydrolysis leaving calcein as a hydrophilic, green fluorescent dye that is released into the medium when the labeled cells die. The read-out of this method is the green fluorescence intensity of the medium. Culture media and supplements like fetal bovine serum (FBS) can be auto-fluorescent, causing background signal that can reach up to 40% of the signal observed at maximum cell death. 5 Other assays include the ATP luminescence assay and the luminescent ADCC Reporter Bioassay. The ATP luminescence assay relies on the quantification of intracellular ATP levels as a read-out for cell viability. As it does not discriminate between target and effector cells the assay is not suitable for ADCC assays. 6, 7 In contrast, the ADCC reporter Bioassay (Promega) relies on the activation of effector cells as a readout, and is therefore applied exclusively for ADCC. 8 We combined and adjusted existing cell viability assays to develop an assay that allows for single cell analysis by high throughput FACS and that corrects for non-specific cell death. In this assay the number of living calcein AM labeled cells that are green fluorescent are quantified by adding a fixed number of calibration beads. With this modified FACS calcein AM retention assay we developed an improved, accurate, high throughput flow cytometer based method to determine cellular cytotoxicity that can be applied in a variety of assays, including CDC and ADCC of suspension and adherent cells.
Materials and Methods

Cell lines
The cell lines Raji, Ramos (Burkitt lymphoma) and SK-BR-3 (breast cancer) (ATCC) were cultured according to manufacturers instructions. Raji and Ramos cells were grown in suspension at a cell density of 4x10 5 -2x10 6 and cultured at 37°C with 5% CO 2 . On the day of the cytotoxicity experiment culture medium was replaced with McCoy's 5A medium (Sigma) supplemented with 2% heat-inactivated fetal bovine serum, and 1x GlutaMAX™ containing 10 nM calcein AM, in a final concentration of 100 µl/well. Cells were incubated with calcein AM at 37°C for 30 minutes, protected from light, and cells in suspension were intermittently agitated.
Effector cells
PBMC were isolated from buffy coats (Sanquin) by density gradient centrifugation and cryopreserved to secure equal PBMC quality for all assays. PBMC from two donors were used (see Table 2 and 3). The NK cell ratio for each PBMC batch was determined by flow cytometry using mouse anti-human CD56 APC (BioLegend) and mouse anti-human CD16 PE/Cy7 (Beckman Coulter). Thawed PBMC were cultured overnight in complete medium for suspension cells at a density of 1x10 6 cells/ml. For ADCC assays on Ramos cells with rituximab, 500 IU/ ml recombinant IL-2 (Aldesleukin) was added during the overnight incubation. The optimal concentration of effector cells was determined at 12.5x10 6 PBMC/ml in complete medium for suspension and adherent cells.
Conventional calcein release assay
Ramos target cells were labeled with 2μM calcein AM as described above. For ADCC, target cells were incubated with antibody (see below) and PBMC for 4 hours, with 2% Triton (Sigma) added for the final 5 minutes to ensure maximum calcein release. After centrifugation, cell free supernatant was transferred to a Cellcarrier plate (Perkin Elmer) to measure relative fluorescence units (RFU) using a HTS multilabel reader (Envision; Perkin Elmer). The percentage of specific lysis was calculated as follows: ((RFU value in respective treatment-RFU value in control (spontaneous release) / (RFU value Triton (maximum release)-RFU value in control (spontaneous release)) x 100. The background of the assay was calculated as follows: (RFU value in control (spontaneous release) / RFU value Triton (maximum release)) x 100.
Lactate dehydrogenase (LDH) assay
Unlabeled Ramos cells were incubated with antibody (see below) and PBMC for 4 hours at 37°C in 5% CO2, with Triton added during the last 5 minutes for maximum LDH release. Cells were incubated with a reaction mixture (Cytotoxicity Detection Kit Plus (Roche)) for 20 minutes at room temperature. The reaction was stopped and optical density was measured at a wavelength of 492 nm on an Envision. The percentage of specific lysis was calculated as described above. PBMC and target cell only conditions were used to measure spontaneous release; for maximum release triton was added. The background of the assay was calculated as described above.
Flow cytometry based calcein retention assay
Calcein AM labeled suspension cells were washed twice, adjusted to a cell concentration of ). This medium control sample was set as 100% survival.
Complement dependent cytotoxicity assay on suspension cells
We then validated the modified FACS calcein AM retention assay for quantifying cell viability by therapeutic antibodies. Rituximab is a CD20-specific monoclonal antibody that induces CDC and ADCC of B cells, including the B cell lines Ramos and Raji. 7 Ramos and Raji target cells were labeled with calcein AM and incubated with complement containing rabbit serum to a final concentration of 10% and rituximab or control antibody. One representative example is depicted in Figure 2A (left panels). Dose-response analysis of rituximab concentrations ranging from 0.5 to 3300 ng/ml yielded sigmoidal curves ( Figure 2B ) and EC50 values of 82 and 24 ng/ml for Ramos and Raji, respectively, with narrow 95% EC50 confidence intervals (Table 1) .
Complement-containing rabbit serum alone was very well tolerated by the cells resulting less than 5% background cell death. Additional visualization of this process was performed with 
Antibody dependent cellular cytotoxicity on suspension cells
To measure ADCC, calcein labeled target cells were incubated with human PBMC from healthy donors. A range of effector-to-target (E:T) cell ratios were tested in duplicate. For both batches of PBMC that were used in these assays, the optimal E:T ratio was 50:1. The percentage of CD56+ NK cells per PBMC sample used in our assays was around 10%, resulting in a NK effector:
target cell ratio of 5:1. Calcein-labeled Ramos and Raji B lymphocytes were incubated with PBMC and different concentrations of rituximab. In Figure 2A (right panels) a representative example is depicted. Dose-response tests again yielded sigmoidal curves with limited variation between duplicates as can be observed by the narrow 95% confidence interval and EC50 values of 1.2 and 1.02 ng/ml for Ramos and Raji cells, respectively ( Figure 2C and Table 2 ). 
Transform of Raji
Control Rituximab
Representative examples of CDC and ADCC as measured by the modified calcein AM retention assay. Ramos cells were used as target cells. Rituximab was added at a concentration of 1000 ng/ml. Antibody dose response curves for the three cytotoxicity assays. Rituximab induced ADCC of Ramos cells with the calcein release assay (open triangles, 49% maximum cell death; EC50 3.7 ng/ml), LDH release assay (open circles, 58% maximum cell death; EC50 3.0 ng/ml) and the modified calcein retention assay (green, closed diamonds, 71% maximum cell death; EC50 2.3 ng/ml).
CDC
In A-C PBMC donor 4 was used, in D and E PBMC donor 14 was used. We then compared the FACS calcein AM retention assay to the calcein release assay and the LDH release assay side by side in one experiment (Table 3) . Spontaneous LDH release was high, resulting in a ~70% background signal in the LDH release assay. The calcein release assay had ~54% background signal whereas the calcein retention assay had a background signal of only 15%. The remaining window of 85% of the signal, which can be used for calculating specific lysis, makes the FACS calcein AM retention assay the most sensitive assay ( figure 2D ). In figure   2E the dose response curves of the three methods to quantify Rituximab induced ADCC of 
Antibody dependent cellular cytotoxicity on adherent cells
We then applied the modified FACS calcein AM retention assay to adherent cells using the breast cancer cell line SK-BR-3. In conventional cytotoxicity assays adherent cells are detached prior to the assay. To overcome detachment-related effects on cell viability, we plated adhe- for trastuzumab on SK-BR-3 cells was 0.17ng/ml (Table 2 ). In all experiments PBMC from donor 4 were used.
Discussion
Established methods to determine the cytotoxicity of any given compound in vitro are negatively affected by non-specific signals caused by auto-fluoresence of target and effector cells and random cell death that leads to underestimations of the activity of the compound under study. To overcome this, we developed a novel cytotoxicity assay in which we combined and optimized established cell viability assays. This resulted in an exceptionally sensitive method that allows for single cell analysis by high throughput FACS. As shown in Table 1 (CDC) and Table 2 (ADCC), the EC50 values obtained with this modified FACS calcein AM retention assay are considerably lower compared to published data. 7, 8, [11] [12] [13] [14] [15] [16] For example, using the chromium 51 ( 51 Cr) release assay 15 and the reporter-based ADCC bioluminescence assay (Promega) 8, 17 to measure ADCC of Raji cells by rituximab yielded an EC50 of around 17 ng/mg (19 vs 16.2).
The LDH release assay generated a somewhat lower EC50 of 12 ng/ml 14 . In our hands, the calcein release assay and the LDH release assay yielded an EC50 of 3.7 ng/ml and 3.0 ng/ml, respectively, while depending on the batch of effector cells used the modified FACS calcein AM retention assay produced an EC50 of 1,2 to 2.3 ng/ml (Table 3 ). The high sensitivity of our assay is the result of a much higher accuracy of compound-specific cell viability analysis as the assay focuses on live cells instead of dead cells. Spontaneous release of enzymes or radioactive isotopes does not interfere with the analysis and background signals are thereby compensated for.
The modified calcein retention assay has other advantages. With its focus on live cells, it allows for less strict timing of analysis as it takes into account all mechanism of cell death (e.g. apoptosis, necroptosis, oncosis). It should be noted that very early apoptotic cells are not detected with any of these methods, as early in the apoptotic pathway the cell membrane is intact and Cr
51
, calcein and LDH are contained in the cell. This can be overcome by co-staining with an early apoptotic marker like Annexin V, which stains the flipped phosphatidylserine.
Furthermore, for laboratories that have a flow cytometer available the assay is relatively cheap compared to commercially available kits, the read-out is simple, and the assay is safe, as it does not employ toxic or radioactive materials.
EC50 values obtained with our assay were highly reproducible with less than 0.1 ng/ml variation, but only when the same batch of PBMCs was used. The effector cell function of PBMC is to a large extent determined by the percentage of NK cells present and their cytotoxic capacity, which is amongst others dependent on the CD16 FcγRIIIa receptor polymorphism. CD16 Fc receptors with a valine at position 158 have a higher affinity for IgG compared to CD16 Fc receptors with a phenylanaline at that position. 18, 19 This may result in more efficient effector function of NK cells, however, it is not the only determinant of effector function. Both batches of PBMC that we used had the same FcγRIIIa receptor polymorphism but were isolated at different time-points and showed different effector function. It has been demonstrated that blood processing can impact on NK cell activation and function, and this may add to the variability of NK cell function in ADCC assays. 20 Thus, the inter-donor variation for effector cells is large, and PBMC should be tested for their ADCC potency before new compounds are investigated. With the use of CD16 expressing NK cell lines more stable and comparable results may be obtained. 21 .
Taken together, we have developed an extremely sensitive, reproducible, high throughput flow cytometer based method to determine cellular cytotoxicity, which can be applied to test the cytotoxicity of compounds in vitro.
